6 results match your criteria: "Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine[Affiliation]"
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Cancer Chemother Pharmacol
March 2021
Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Purpose: Resistance to treatment with inhibitors of mammalian target of rapamycin (mTOR) is partially mediated by activation of epidermal growth factor receptor (EGFR). We conducted a phase I study to determine the recommended phase II dose (RP2D) and dose-limiting toxicities (DLT) of temsirolimus (mTOR inhibitor) combined with erlotinib (EGFR inhibitor) in patients with refractory solid tumors.
Methods: Standard "3 + 3" design was used for dose escalation.
Know Thy Enemy-Understanding the Role of Inflammation in Severe Acute Pancreatitis.
Gastroenterology
January 2020
Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida. Electronic address:
NFκB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12.
Gastroenterology
September 2018
Department of Surgery, Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida. Electronic address:
Background & Aims: Immunotherapies are ineffective against pancreatic cancer. We investigated whether the activity of nuclear factor (NF)κB in pancreatic stromal cells contributes to an environment that suppresses antitumor immune response.
Methods: Pancreata of C57BL/6 or Rag1 mice were given pancreatic injections of a combination of Kras; Trp53 ; Pdx-1cre (KPC) pancreatic cancer cells and pancreatic stellate cells (PSCs) extracted from C57BL/6 (control) or mice with disruption of the gene encoding the NFκB p50 subunit (Nfkb1 or p50 mice).
Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response.
Gastroenterology
July 2018
Department of Surgery at Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine, Miami, Florida. Electronic address:
We studied the effects of gut microbiome depletion by oral antibiotics on tumor growth in subcutaneous and liver metastases models of pancreatic cancer, colon cancer, and melanoma. Gut microbiome depletion significantly reduced tumor burden in all the models tested. However, depletion of gut microbiome did not reduce tumor growth in Rag1-knockout mice, which lack mature T and B cells.
View Article and Find Full Text PDFImportance: The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are highly enriched for BRAF V600 mutations and have been previously shown to be responsive to treatment with vemurafenib, an inhibitor of the BRAF V600 kinase. However, the long-term efficacy and safety of prolonged vemurafenib use in these patients are not defined. Here we analyze the final efficacy and safety data for vemurafenib in patients with ECD and LCH enrolled in the VE-BASKET study.
View Article and Find Full Text PDFGiant Basal Cell Carcinomas Arising on the Bilateral Forearms of a Patient: A Case Report and Review of Nonsurgical Treatment Options.
Case Rep Dermatol
December 2016
Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Giant basal cell carcinomas (GBCCs) are large basal cell carcinomas (BCCs; <5 cm) with a greater propensity to invade and metastasize than standard BCCs. The presence of 2 GBCCs in a single individual is rare. We present the case of a 71-year-old Caucasian male with bilateral GBCCs on the dorsal forearms, measuring 130 cm and 24 cm, respectively, that developed over a 21-year period.
View Article and Find Full Text PDF